Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder
- PMID: 24132760
- PMCID: PMC6599863
- DOI: 10.1002/14651858.CD003196.pub2
Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder
Abstract
Background: Bipolar disorder is a recurrent illness that is amongst the top 30 causes of disability worldwide and is associated with significant healthcare costs. In the past, emphasis was placed solely on the treatment of acute episodes of bipolar disorder; recently, the importance of episode prevention and of minimisation of iatrogenicity has been recognised. For many years, lithium was the only mood stabiliser in common use, and it remains an agent of first choice in the preventative treatment of bipolar disorder. However, an estimated 20% to 40% of patients may not respond adequately to lithium. Valproate is an anticonvulsant drug that has been shown to be effective in acute mania and is frequently used in maintenance treatment of bipolar disorder. When the acceptability of long-term treatment is considered, together with efficacy, the adverse event profile of a medication is also important. This is an update of a Cochrane review first published in 2001 and last updated in 2009.
Objectives: 1. To determine the efficacy of valproate continuation and maintenance treatment:a) in preventing or attenuating manic, depressive and mixed episodes of bipolar disorder;b) in preventing or attenuating episodes of bipolar disorder in patients with rapid cycling disorder; and; c) in improving patients' general health and social functioning, as measured by global clinical impression, employment and marital stability.2. To review the acceptability to patients of long-term valproate treatment, as measured by numbers of dropouts and reasons for dropping out, by compliance and by reference to patients' expressed views regarding treatment.3. To investigate the adverse effects of valproate treatment (including general prevalence of side effects) and overall mortality rates.
Search methods: Search of the Cochrane Register of Controlled Trials and the Cochrane Depression, Anxiety and Neurosis Group Register (CCDANCTR) (to January 2013), which includes relevant randomised controlled trials from the following bibliographic databases: The Cochrane Library (all years), EMBASE, (1974 to date), MEDLINE (1950 to date) and PsycINFO (1967 to date). No language restrictions were applied. Reference lists of relevant papers and previous systematic reviews were handsearched. Pharmaceutical companies marketing valproate and experts in this field were contacted for supplemental data.
Selection criteria: Randomised controlled trials allocating participants with bipolar disorder to long-term treatment with valproate or any other mood stabiliser, or antipsychotic drugs, or placebo. Maintenance treatment was defined as treatment instituted specifically or mainly to prevent further episodes of illness.
Data collection and analysis: Three review authors independently extracted data. A double-entry procedure was employed by two review authors. Information extracted included study characteristics, participant characteristics, intervention details and outcome measures in terms of efficacy, acceptability and tolerability. For dichotomous data, risk ratios were calculated with 95% confidence intervals (CIs). For statistically significant results, we calculated the number needed to treat for an additional beneficial outcome (NNTB) and the number needed to treat for an additional harmful outcome (NNTH). For continuous data, mean differences (MDs) or standardised mean differences (SMDs) were calculated along with 95% CIs. MDs were used when the same scale was used to measure an outcome; SMDs were employed when different scales were used to measure the same outcome. The primary analysis used a fixed-effect model. Binary outcomes were calculated on a strict intention-to-treat (ITT) basis; dropouts were included in this analysis. When data were missing and the method of "last observation carried forward" (LOCF) had been used to do an ITT analysis, then the LOCF data were used.
Main results: Six randomised controlled trials (overall 876 participants) lasting 6 to 24 months were included. Two studies (overall 312 participants) compared valproate with placebo, four studies (overall 618 participants) valproate with lithium, one study (overall 23 participants) valproate with olanzapine and one study (overall 220 participants) valproate with the combination of valproate plus lithium. In terms of study quality, most studies reported the methods used to generate random sequence; however, only one study reported enough details on allocation concealment. Four of six included studies described their design as "double blind", but only two trials reported full details about blinding. Valproate was more effective than placebo in preventing study withdrawal due to any mood episode (RR 0.68, 95% CI 0.49 to 0.93; NNTB 8), but no difference in efficacy was found between valproate and lithium (RR 1.02, 95% CI 0.87 to 1.20). Valproate was associated with fewer participants dropping out of treatment for any cause when compared with placebo or lithium (RR 0.82, 95% CI 0.71 to 0.95 and RR 0.87, 95% CI 0.77 to 0.98, respectively). However, combination therapy with lithium plus valproate was more likely to prevent relapse than was monotherapy with valproate (RR 0.78, 95% CI 0.63 to 0.96). Significant differences in adverse event frequencies were found, and lithium was associated with more frequent diarrhoea, polyuria, increased thirst and enuresis, whereas valproate was associated with increased sedation and infection.
Authors' conclusions: Limited evidence supports the efficacy of valproate in the long-term treatment of bipolar disorder. Clinicians and patients should consider acceptability and tolerability profile when choosing between lithium and valproate-their combination or other agents-as long-term treatment for bipolar disorder.
Conflict of interest statement
Andrea Cipriani participated in the BALANCE trial as Italy's chief investigator.
Keith Reid declares no conflicting interests.
Allan H Young has sat on advisory boards and has received honoraria for lectures from sanofi‐aventis, makers of a form of valproate, and also participated in the BALANCE trial, for which sanofi‐aventis donated study medications.
Dr Karine Macritchie has worked on a project supported by an award NS‐EU‐166 from the Translational Medicine Research Collaboration. This consortium comprises the Universities of Aberdeen, Dundee, Edinburgh and Glasgow, the four associated NHS Health Boards (Grampian, Tayside, Lothian and Greater Glasgow and Clyde), Scottish Enterprise and Pfizer (formerly Wyeth). Several pharmaceutical companies have paid her institution for lectures, educational presentations/material and research.
John Geddes currently receives research funding from the UK Medical Research Council, the UK Economic and Social Research Council, the National Institute for Health Research, and the Stanley Medical Research Institute. He was expert witness for Dr Reddy's Laboratories, he is Chief Investigator on the CEQUEL trial to which GlaxoSmithKline has contributed and for which it has supplied investigational drugs and placebo. He is also the chief investigator of the BALANCE trial.
Figures
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6599863/bin/nCD003196-AFig-FIG01.gif)
![Figure 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6599863/bin/nCD003196-AFig-FIG02.gif)
![Figure 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6599863/bin/nCD003196-AFig-FIG03.gif)
![Figure 4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6599863/bin/nCD003196-AFig-FIG04.gif)
![Figure 5](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6599863/bin/nCD003196-AFig-FIG05.gif)
![Figure 6](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6599863/bin/nCD003196-AFig-FIG06.gif)
![Analysis 1.1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6599863/bin/nCD003196-CMP-001-01.gif)
![Analysis 1.2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6599863/bin/nCD003196-CMP-001-02.gif)
![Analysis 1.3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6599863/bin/nCD003196-CMP-001-03.gif)
![Analysis 1.4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6599863/bin/nCD003196-CMP-001-04.gif)
![Analysis 2.1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6599863/bin/nCD003196-CMP-002-01.gif)
![Analysis 2.2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6599863/bin/nCD003196-CMP-002-02.gif)
![Analysis 2.3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6599863/bin/nCD003196-CMP-002-03.gif)
![Analysis 2.4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6599863/bin/nCD003196-CMP-002-04.gif)
![Analysis 2.5](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6599863/bin/nCD003196-CMP-002-05.gif)
![Analysis 2.6](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6599863/bin/nCD003196-CMP-002-06.gif)
![Analysis 2.7](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6599863/bin/nCD003196-CMP-002-07.gif)
![Analysis 2.8](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6599863/bin/nCD003196-CMP-002-08.gif)
![Analysis 2.9](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6599863/bin/nCD003196-CMP-002-09.gif)
![Analysis 2.10](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6599863/bin/nCD003196-CMP-002-10.gif)
![Analysis 2.11](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6599863/bin/nCD003196-CMP-002-11.gif)
![Analysis 3.1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6599863/bin/nCD003196-CMP-003-01.gif)
![Analysis 3.2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6599863/bin/nCD003196-CMP-003-02.gif)
![Analysis 3.3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6599863/bin/nCD003196-CMP-003-03.gif)
![Analysis 4.1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6599863/bin/nCD003196-CMP-004-01.gif)
![Analysis 4.2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6599863/bin/nCD003196-CMP-004-02.gif)
![Analysis 4.3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6599863/bin/nCD003196-CMP-004-03.gif)
![Analysis 4.4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6599863/bin/nCD003196-CMP-004-04.gif)
![Analysis 4.5](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6599863/bin/nCD003196-CMP-004-05.gif)
![Analysis 4.6](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6599863/bin/nCD003196-CMP-004-06.gif)
![Analysis 4.7](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6599863/bin/nCD003196-CMP-004-07.gif)
![Analysis 4.8](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6599863/bin/nCD003196-CMP-004-08.gif)
![Analysis 4.9](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6599863/bin/nCD003196-CMP-004-09.gif)
![Analysis 4.10](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6599863/bin/nCD003196-CMP-004-10.gif)
![Analysis 5.1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6599863/bin/nCD003196-CMP-005-01.gif)
![Analysis 5.2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6599863/bin/nCD003196-CMP-005-02.gif)
![Analysis 5.3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6599863/bin/nCD003196-CMP-005-03.gif)
![Analysis 5.4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6599863/bin/nCD003196-CMP-005-04.gif)
![Analysis 5.5](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6599863/bin/nCD003196-CMP-005-05.gif)
![Analysis 5.6](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6599863/bin/nCD003196-CMP-005-06.gif)
![Analysis 5.7](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6599863/bin/nCD003196-CMP-005-07.gif)
![Analysis 5.8](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6599863/bin/nCD003196-CMP-005-08.gif)
![Analysis 5.9](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6599863/bin/nCD003196-CMP-005-09.gif)
![Analysis 5.10](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6599863/bin/nCD003196-CMP-005-10.gif)
Update of
-
Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder.Cochrane Database Syst Rev. 2001;(3):CD003196. doi: 10.1002/14651858.CD003196. Cochrane Database Syst Rev. 2001. Update in: Cochrane Database Syst Rev. 2013 Oct 17;(10):CD003196. doi: 10.1002/14651858.CD003196.pub2. PMID: 11687047 Updated. Review.
Similar articles
-
Aripiprazole alone or in combination for acute mania.Cochrane Database Syst Rev. 2013 Dec 17;(12):CD005000. doi: 10.1002/14651858.CD005000.pub2. Cochrane Database Syst Rev. 2013. PMID: 24346956 Review.
-
Olanzapine in long-term treatment for bipolar disorder.Cochrane Database Syst Rev. 2009 Jan 21;(1):CD004367. doi: 10.1002/14651858.CD004367.pub2. Cochrane Database Syst Rev. 2009. PMID: 19160237 Review.
-
[Antipsychotics in bipolar disorders].Encephale. 2004 Sep-Oct;30(5):417-24. doi: 10.1016/s0013-7006(04)95456-5. Encephale. 2004. PMID: 15627046 Review. French.
-
Valproate for acute mood episodes in bipolar disorder.Cochrane Database Syst Rev. 2003;(1):CD004052. doi: 10.1002/14651858.CD004052. Cochrane Database Syst Rev. 2003. PMID: 12535506 Review.
-
Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder.Cochrane Database Syst Rev. 2001;(3):CD003196. doi: 10.1002/14651858.CD003196. Cochrane Database Syst Rev. 2001. Update in: Cochrane Database Syst Rev. 2013 Oct 17;(10):CD003196. doi: 10.1002/14651858.CD003196.pub2. PMID: 11687047 Updated. Review.
Cited by
-
Carbapenems as Antidotes for the Management of Acute Valproic Acid Poisoning.Pharmaceuticals (Basel). 2024 Feb 17;17(2):257. doi: 10.3390/ph17020257. Pharmaceuticals (Basel). 2024. PMID: 38399472 Free PMC article.
-
Bipolar Affective Disorder: A Case of Antidepressant-Induced Hypomania.Cureus. 2020 Dec 31;12(12):e12399. doi: 10.7759/cureus.12399. eCollection 2020 Dec. Cureus. 2020. PMID: 38347916 Free PMC article.
-
Advances in the role of the GADD45 family in neurodevelopmental, neurodegenerative, and neuropsychiatric disorders.Front Neurosci. 2024 Jan 25;18:1349409. doi: 10.3389/fnins.2024.1349409. eCollection 2024. Front Neurosci. 2024. PMID: 38332860 Free PMC article. Review.
-
Early cellular and synaptic changes in dopaminoceptive forebrain regions of juvenile mice following gestational exposure to valproate.Front Neuroanat. 2023 Aug 3;17:1235047. doi: 10.3389/fnana.2023.1235047. eCollection 2023. Front Neuroanat. 2023. PMID: 37603782 Free PMC article.
-
Pharmacological Strategies for Bipolar Disorders in Acute Phases and Chronic Management with a Special Focus on Lithium, Valproic Acid, and Atypical Antipsychotics.Curr Neuropharmacol. 2023;21(4):935-950. doi: 10.2174/1570159X21666230224102318. Curr Neuropharmacol. 2023. PMID: 36825703 Free PMC article.
References
References to studies included in this review
-
- Altamura AC, Russo M, Vismara S, Mundo E. Comparative evaluation of olanzapine efficacy in the maintenance treatment of bipolar disorder. Journal of Clinincal Psychopharmacology 2004;24:454‐6. - PubMed
-
- Geddes JR, Goodwin GM, Rendell J, Azorin JM, Cipriani A, Ostacher MJ, et al. Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open‐label trial. Lancet 2010;375(9712):385‐95. [PUBMED: 20092882] - PubMed
- Geddes JR, Rendell JM. Update on the progress of BALANCE. Abstracts of the Sixth International Conference on Bipolar Disorder, 16‐18 June 2005, Pittsburgh, Pennsylvania, USA. Bipolar Disorders 2005;7(Suppl 2):58. - PubMed
- Geddes JR, Rendell JM, Goodwin GM, for the BALANCE Investigators. BALANCE: a large simple trial of maintenance treatment for bipolar disorder. World Psychiatry 2002;1(1):48‐51. - PMC - PubMed
- Rendell JM, Juszczak E, Hainsworth J, Gucht E, Healey C, Morriss R, et al. Developing the BALANCE trial—the role of the pilot study and start‐up phase. Bipolar Disorders 2004;6(1):26‐31. - PubMed
-
- Bowden CL, Calabrese JR, McElroy SL, Gyulai L, Wassef A, Petty F, et al. A randomised placebo‐controlled 12 month trial of divalproex and lithium in the treatment of outpatients with bipolar I disorder. Archives of General Psychiatry 2000;57(5):481‐9. - PubMed
- Gyulai L, Bowden CL, Calabrese JR, McElroy SL, Petty F, Risch SC, et al. Efficacy of divalproex for bipolar depression. 153rd Annual Meeting of the American Psychiatric Association, 2000 May 13‐18, Chicago, IL. NR464.
-
- Calabrese JR, Shelton MD, Rapport DJ, Youngstrom EA, Jackson K, Bilali S, et al. A 20‐month, double‐blind, maintenance trial of lithium versus divalproex in rapid‐cycling bipolar disorder. The American Journal of Psychiatry 2005;162(11):2152‐61. [PUBMED: 16263857] - PubMed
- Shelton MD 3rd, Rapport DJ, Youngstrom EA, Elhaj O, Bilali SR, Findling RL, et al. Is rapid cycling a predictor of nonresponse to lithium?. 157th Annual Meeting of the American Psychiatric Association; 2004 May 1‐6; New York, NY, USA. NR759.
-
- Findling RL, McNamara NK, Youngstrom EA, Stansbrey R, Gracious BL, Reed MD, et al. Double‐blind 18‐month trial of lithium versus divalproex maintenance treatment in pediatric bipolar disorder. Journal of the American Academy of Child and Adolescent Psychiatry 2005;44(5):409‐17. [PUBMED: 15843762] - PubMed
References to studies excluded from this review
-
- Bristol‐Myers Squibb. Efficacy of aripiprazole in combination with valproate or lithium in the treatment of mania in patients with bipolar I disorder partially nonresponsive to valproate or lithium monotherapy, 2006. http://www.clinicaltrials.gov/ct2/show/NCT00257972 (accessed 3 October 2....
- Vieta E, T'joen C, McQuade RD, Carson WH Jr, Marcus RN, Sanchez R, et al. Efficacy of adjunctive aripiprazole to either valproate or lithium in bipolar mania patients partially nonresponsive to valproate/lithium monotherapy: a placebo‐controlled study. American Journal of Psychiatry 2008;165(10):1316‐25. - PubMed
-
- Pfizer. A three‐week, double‐blind, multicenter, placebo‐controlled study evaluating the efficacy and safety of add‐on oral ziprasidone in subjects with acute mania treated with lithium or divalproex, 2006. http://www.clinicaltrials.gov/ct2/show/NCT00312494 (accessed 3 October 2....
-
- Revicki DA, Hirschfeld RM, Ahearn EP, Weisler RH, Palmer C, Keck PE Jr. Effectiveness and medical costs of divalproex versus lithium in the treatment of bipolar disorder: results of a naturalistic clinical trial. Journal of Affective Disorders 2005;86(2‐3):183‐93. [PUBMED: 15935238] - PubMed
-
- Tohen M, Ketter TA, Zarate CA, Suppes T, Frye M, Altshuler L, et al. Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47‐week study. The American Journal of Psychiatry 2003;160(7):1263‐71. [PUBMED: 12832240] - PubMed
References to studies awaiting assessment
-
- Bowden CL, Singh V, Weisler R, Thompson P, Chang X, Quinones M, et al. Lamotrigine vs. lamotrigine plus divalproex in randomized, placebo‐controlled maintenance treatment for bipolar depression. Acta psychiatrica Scandinavica 2012;126(5):342‐50. - PubMed
-
- Abbott. A randomized, double‐blind study of depakote monotherapy, olanzapine monotherapy, and combination therapy of depakote plus olanzapine in stable subjects during the maintenance phase of Bipolar Illness. ClinicalTrials.gov2003:http://clinicaltrials.gov/ct2/show/NCT00071253 (accessed 11 January 2013) [Status of study: terminated].
Additional references
-
- American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder. American Journal of Psychiatry 1994;151(12 Suppl):1‐36. - PubMed
-
- American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th edition, text revision. Washington, DC: Author, 2000.
References to other published versions of this review
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous